SCHEMBL19079591

SCHEMBL19079591

CC(C)(C)OC(=O)N[C@H]1CC[C@H](NC(=O)c2noc(C3CC3)c2I)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 2/20 0.39
KDM1A O60341 1/20 0.38
MAOB P27338 1/20 0.38
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38
TYK2 P29597 1/20 0.38
JAK3 P52333 1/20 0.38
BTK Q06187 1/20 0.37
DRD2 P14416 2/20 0.36
EPHX1 P07099 1/20 0.36
CTSK P43235 2/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
PBK Q96KB5 1/20 0.35
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35
LIPG Q9Y5X9 1/20 0.35
SMYD3 Q9H7B4 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19064370 0.85 SMN1; SMN2 (0.42) SMN1; SMN2LMNAGAAKDM1AMAOB
SCHEMBL19064371 0.85 SMN1; SMN2 (0.42) SMN1; SMN2LMNAGAAKDM1AMAOB
SCHEMBL19079593 0.84 SMN1; SMN2 (0.41) SMN1; SMN2LMNAGAAKDM1AMAOB
SCHEMBL19079592 0.82 SMN1; SMN2 (0.40) SMN1; SMN2LMNAGAAKDM1AMAOB
SCHEMBL19064398 0.81 NPC1 (0.40) SMN1; SMN2LMNANPC1RAB9ATP53
SCHEMBL19064399 0.81 NPC1 (0.40) SMN1; SMN2LMNANPC1RAB9ATP53
SCHEMBL19079160 0.80 SMYD3 (0.53) SMN1; SMN2NPC1RAB9ATP53MAPT
SCHEMBL17594834 0.79 LMNA (0.37) SMN1; SMN2LMNAGAAKDM1AMAOB
SCHEMBL17594833 0.79 LMNA (0.37) SMN1; SMN2LMNAGAAKDM1AMAOB
SCHEMBL19742959 0.74 NPC1 (0.64) NPC1RAB9ASMYD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200148650-A1 ISOXAZOLE CARBOXAMIDE COMPOUNDS Epizyme, Inc. 2020-05-14 US disclosed
US-10428029-B2 Isoxazole carboxamide compounds Epizyme, Inc. (US) 2019-10-01 US disclosed
US-20170190676-A1 Isoxazole Carboxamide Compounds Epizyme, Inc. (US) 2017-07-06 US disclosed
US-20170190676-A1 Isoxazole Carboxamide Compounds Epizyme, Inc. (US) 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10428029-B2 Isoxazole carboxamide compounds SMYD3, SMYD2, SNRPD3 SMN1; SMN2 248/4885LMNA 4283/4885GAA 2791/4885
US-20170190676-A1 Isoxazole Carboxamide Compounds SMYD3, SMYD2, SNRPD3 SMN1; SMN2 248/4885LMNA 4283/4885GAA 2791/4885
US-20200148650-A1 ISOXAZOLE CARBOXAMIDE COMPOUNDS SMYD3, SMYD2, SNRPD3 SMN1; SMN2 223/4885LMNA 4322/4885GAA 2747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.